LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

12-Jul-2022 - LegoChem Biosciences Inc. (LCB) and Glycotope GmbH (Glycotope) have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate (ADC) by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational tumor targeting antibodies. Under the terms ...

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform

Expansion of senior team to focus on drug discovery and development

24-Mar-2022 - Glycotope GmbH announces that is has completed a re-focusing of its strategy to better deliver value from its powerful, proprietary glycobiology-informed technology platform. The Company has also expanded its senior leadership team to accelerate the execution and delivery of this ...

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH

01-Feb-2022 - Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, and CantonBio Deutschland GmbH, a subsidiary of Canton Biologics Co. Ltd., a leading Chinese CDMO, announced the successful completion of CantonBio’s acquisition of ...

Celonic Acquires Glycotope’s Bio-manufacturing Facility

03-Nov-2017 - Celonic AG and Glycotope announced the successful completion of Celonic’s acquisition of Glycotope’sbio-manufacturing facility in Heidelberg, Germany. The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with ...

Glycotope Enrolls First Patients in Phase I Trial with TrasGEX, a Glycooptimized HER2 Biobetter Antibody

20-Sep-2011 - Glycotope GmbH announced the enrollment of the first patients in a phase I dose finding trial to evaluate safety and tolerability of TrasGEX™. TrasGEX™ is a biobetter of the marketed Trastuzumab / Herceptin™ targeting the HER2-receptor, commonly overexpressed in a variety of cancers. TrasGEX™ has ...

Glycotope Biotechnology Expands GMP Production Facility to 11 kg Antibody per Year

08-Apr-2011 - Glycotope Biotechnology GmbH has initiated the setup of further clean room facilities as a first step in the expansion of its GMP-production capacities. By mid 2011, the company will thus be able to produce 4kg of recombinant antibodies per year and up to 11 kg upon completion of works towards ...

Glycotope Receives Innovation Award Berlin Brandenburg 2010

17-Dec-2010 - Glycotope GmbH has won the innovation award 2010 jointly presented by the German states of Berlin and Brandenburg in recognition of the company’s GlycoExpress™ technology platform. GlycoExpress™ combines a very efficient improvement of the activities and side effects of a broad range of protein ...

Glycotope Winner at STEP Award 2010

22-Nov-2010 - Glycotope GmbH has been awarded with the 2010 STEP-Award for financing. Glycotope was selected for its strategically aligned and long-term funding concept. CFO Dr. Franzpeter Bracht stated: “In addition to our outstanding technology, from the beginning we have put great emphasis on a balanced ...

Glycotope received regulatory approval for glycooptimized and fully human glycosylated antibody CetuGEX

13-Aug-2010 - Glycotope GmbH, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope's next generation antibody CetuGEX (GT-MAB 5.2-GEX) for the treatment of various solid cancers. “For Glycotope, the approval of CetuGEX, our 2nd antibody in the clinic, ...

Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX

Glycotope Enrolls First Patients in Clinical Trial

05-Aug-2010 - Glycotope GmbH has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers. “For Glycotope, the approval of CetuGEX™, our second antibody in the ...